Durable Vitiligo Responses With Topical Ruxolitinib

(MedPage Today) -- NEW ORLEANS -- Patients who discontinued topical ruxolitinib (Opzelura) for vitiligo retained new pigmentation for as long as a year, according to a study of planned withdrawal.
Almost 40% of patients maintained their response...

Source: MedPage Today Dermatology - March 21, 2023 Category: Dermatology Source Type: news